Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol

Completed · Phase 4 · Has a placebo group

Conditions studied: Mucociliary Clearance

In brief

The purpose of this study is to determine whether lung mucociliary clearance (MCC) can be significantly enhanced in healthy subjects by one week of inhalation of nebulized levalbuterol aerosol, as compared to racemic albuterol or placebo. Subjects will inhale one week of levalbuterol, one week of racemic albuterol, and one week of placebo, in a randomized order.

Key facts

Study ID

NCT00325767

Run by

Johns Hopkins University

People needed

10

Starts

2004-05-01

Expected to finish

2005-09-01

Last updated by the study team

2006-05-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• non-smoking males and non-pregnant females greater than or equal to 18 years of age
• forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) greater than or equal to 80% of predicted values
• normal systolic and diastolic blood pressures

You may not qualify if…

• history of heart disease, irregular heartbeat, hypertension
• history of diabetes, hyperthyroid
• history of pneumonia, tuberculosis
• history of seizure disorder, depression, hospitalization in the last month for non-elective purposes, cold or flu in the previous three months

Where it is running

• Eudowood Division of Pediatric Respiratory Sciences — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.